Therabene
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2020 in Mansfield, Massachusetts, U.S. |
| Founder | Mario DiPaola |
| Headquarters | Norwood, Massachusetts, U.S. |
Key people | Mario DiPaola (CEO)[1] Zoser Mohamed (President) Oscar Kashala (CMO) |
| Website | www |
Therabene is an American biotechnology company founded in 2020. It researches a class of drugs called PROTACs, which are designed to degrade disease-related proteins, with a focus on targets such as CDK9 and MYC for cancer therapy.[2]
History
Therabene was founded in 2020 by Mario DiPaola, initially operating from the Mansfield Bio-Incubator.[3][4] The company later relocated its headquarters to Norwood, Massachusetts.[5]
In November 2024, the company announced preclinical results for two molecules showing tumor reduction in a triple-negative breast cancer model.[6] In August 2025, Therabene appointed Oscar L. Kashala as chief medical officer to advance its clinical pipeline.[7][8]
Products and research
Therabene is developing inhibitors and degraders, targeting CDK9 and MYC Protein to downregulate oncogenic proteins in cancers. Its pipeline includes TB-003, TB-008, and TB-010, TB-M002, which are in preclinical stages for treating triple-negative breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer.[9][10]
The company's research integrates computational and experimental methods for inhibitors and degraders discovery and development.[11]
References
- ^ "Therabene Mario DiPaola PhD/MBA Protein Degraders Cancer". CEOCFO Magazine. July 17, 2023. Retrieved January 16, 2026.
- ^ Koirala, Mahesh; DiPaola, Mario. "Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders". PubMed Central. Retrieved January 16, 2026.
- ^ Hanley, Kenneth (2024-08-07). "Mario DiPaola, PhD, MBA". Top Execs. Retrieved 2026-02-13.
- ^ "Company Spotlight: Therabene". Mansfield Bio-Incubator. January 12, 2022. Retrieved January 16, 2026.
- ^ "Therabene Inc. Appoints Dr. Oscar L. Kashala as Chief Medical Officer and Executive Vice President of Global Clinical Development". PharmiWeb.com. August 6, 2025. Retrieved January 16, 2026.
- ^ "Therabene molecules show promise in triple-negative breast cancer model". BioWorld. November 22, 2024. Retrieved January 16, 2026.
- ^ "Therabene Inc. Appoints Oscar L. Kashala as CMO and EVP of Global Clinical Development". FirstWord Pharma. August 6, 2025. Retrieved January 16, 2026.
- ^ "Therabene Appoints Dr. Oscar Kashala as CMO to Advance Protein Degrader Pipeline for Hard-to-Treat Cancers". MedPath. Retrieved January 16, 2026.
- ^ "TB-010 - Drug Targets, Indications, Patents". Patsnap Synapse. December 17, 2025. Retrieved January 16, 2026.
- ^ "Discovery of a first-in-class CDK9 degrader targeting oncogenic transcription networks in hematologic and solid tumors". Molecular Cancer Therapeutics. 24 (10 Supplement): B125. October 2025. Retrieved 2026-02-13.
- ^ "Recent Developments in Cyclin-Dependent Kinase (CDK) PROTAC in Cancer Therapy". ACS Medicinal Chemistry Letters. November 24, 2025. Retrieved January 16, 2026.